-
RBC Capital Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP)
-
RBC Capital Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP)
-
RBC Capital Starts Corbus Pharmaceuticals (CRBP) at Outperform, 'Reinventing Themselves With Promising ADC and Obesity Assets'
-
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
-
Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences
-
Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences
-
RBC Capital Downgrades Corbus Pharmaceuticals (CRBP) to Sector Perform
-
Pre-Open Stock Movers 07/07: (NVAX) (VSLR) (RUN) Higher; (EOLS) (CLLS) (MARK) Lower (more...)
-
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
-
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
-
Corbus Pharmaceuticals (CRBP) PT Lowered to $22 at RBC Capital, Positive Into Two Shots on Goal
-
Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Corbus Pharma (CRBP) Prices 6.67M Share Common Offering at $6/Sh
-
Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Corbus Pharma (CRBP) Announces Proposed Public Offering of Common Stock
-
Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in May
-
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in May
-
Corbus Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Corbus Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
-
UPDATE: Corbus Pharma (CRBP) Prices 5.39M Share Common Offering at $6.50/Sh
-
Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Corbus Pharma (CRBP) to Offer Common Stock
-
Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Pre-Open Movers 12/07: (CRON) (AOBC) (AVGO) Higher; (VIVE) (BIG) (ULTA) Lower (more...)
-
UPDATE: RBC Capital Starts Corbus Pharmaceuticals (CRBP) at Outperform
-
Corbus Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference

